AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9014669
Drug: Selective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective treatment of DVT after confirmation of diagnosis
Trial: 1642678
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of clentiazem (30 mg)
Trial: 1642678
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of clentiazem (30 mg daily for 2 weeks)
Trial: 24908970
Drug: High-dose tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tamoxifen therapy in combination with chemotherapy
Trial: 28912956
Drug: SRT2104 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 (2.0 g/day)
Trial: 20837462
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus carboplatin AUC 6 for 4 cycles followed by maintenance pemetrexed
Trial: 20837462
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 plus carboplatin AUC 6 plus bevacizumab 15 mg/kg for 4 cycles followed by maintenance bevacizumab
Trial: 16883902
Drug: Tiepi Fengdou
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiepi Fengdou Capsule (TFC)
Trial: 16883902
Drug: Shengmai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai Capsule (Control)
Trial: 11762816
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate 90 mg monthly
Trial: 11762816
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate 1,600 mg daily
Trial: 11762816
Drug: Intravenous clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clodronate followed by oral clodronate
Trial: 3565931
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of isotonic saline
Trial: 24259556
Drug: Zinc citrate
RxNorm normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc citrate (10 mg)
Trial: 24259556
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (10 mg)
Trial: 24259556
Drug: Zinc oxide
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide (10 mg)
Trial: 23202814
Drug: Methods video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methods video (focused on intrauterine device and contraceptive implant)
Trial: 17664051
Drug: Naltrexone 150
RxNorm normalized name: METHYLNALTREXONE 150MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 150 mg/day for 12 weeks
Trial: 10029562
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (3.0 ng x min‐1 x kg‐1 for 30 min followed by dose increment every 30 min until mean blood pressure increased by 25 mmHg)
Trial: 10029562
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (10(‐9), 10(‐8), 10(‐7) mol/l) in cultured human vascular endothelial cells
Trial: 10029562
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (AT1 receptor inhibitor)
Trial: 10029562
Drug: Actinomycin D
RxNorm normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actinomycin D (RNA synthesis inhibitor)
Trial: 10029562
Drug: Cycloheximide (protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloheximide (protein synthesis inhibitor)
Trial: 453298
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (550 mg initially, followed by 275 mg every 6 hours as needed)
Trial: 31307843
Drug: EAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA supplementation (15 g daily)
Trial: 31307843
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (supervised progressive vigorous treadmill walking 3 times weekly)
Trial: 29538089
Drug: Treatment Responders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Responders (TRs)
Trial: 29538089
Drug: Treatment Nonresponders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Nonresponders (TNRs)
Trial: 29538089
Drug: Medication-assisted treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-assisted treatment
Trial: 29538089
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment nonresponse
Trial: 29538089
Drug: Baseline SUD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline SUD treatment
Trial: 24614377
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (400/100 mg BID)
Trial: 24614377
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose (600/150 mg BID)
Trial: 24614377
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (400/100 mg BID) after childbirth
Trial: 24614377
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose (600/150 mg BID) after childbirth
Trial: 15895892
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight HA (Hylan G‐F 20) injections
Trial: 15895892
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight HA (Orthovisc) injections
Trial: 15895892
Drug: Both HA
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HA preparations (High molecular weight and Low molecular weight)
Trial: 7340376
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 μg.kg‐1
Trial: 7340376
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 μg.kg‐1
Trial: 7340376
Drug: Fentanyl 30
RxNorm normalized name: fentaNYL 300 mcg oral lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 30 μg.kg‐1
Trial: 6429481
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 17 beta-oestradiol 2 mg plus oestriol 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg plus oestriol 0.5 mg for 6 days
Trial: 6429481
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg for 6 days (without oestriol)
Trial: 29284788
Drug: Dose 1
RxNorm normalized name: Aldose 1-epimerase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 Curry
Trial: 29284788
Drug: Dose 2
RxNorm normalized name: Fluzone High-Dose 2011-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2 Curry
Trial: 29284788
Drug: Dose 0
RxNorm normalized name: Femhrt Low Dose 0.5/2.5 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 0 Control
Trial: 26517858
Drug: Duloxetine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (titrated up to 120 mg/day)
Trial: 24255991
Drug: Bathing in
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bathing in geothermal seawater combined with NB‐UVB therapy three times a week
Trial: 24255991
Drug: Intensive daily
RxNorm normalized name: OATMEAL 2 g in 100 g TOPICAL CREAM [ECZEMA INTENSIVE DAILY RELIEF BODY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive daily treatment involving bathing in geothermal seawater combined with NB‐UVB therapy
Trial: 24255991
Drug: NB‐UVB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB therapy alone three times a week
Trial: 19915480
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg + Haloperidol 1.5 mg
Trial: 19915480
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg + Placebo
Trial: 17975386
Drug: Standard timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timing of renal replacement therapy
Trial: 16249547
Drug: Pitavastatin 1
RxNorm normalized name: PITAVASTATIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 1 mg/day for 12 months (group B1)
Trial: 11844826
Drug: Vorozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole (2.5 mg per day for 12 weeks)
Trial: 11844826
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg per day for 12 weeks)
Trial: 2104074
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (500 mg t.d.s.)
Trial: 24398053
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg once daily at bedtime
Trial: 19463030
Drug: Psychoeducational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational music therapy
Trial: 8212823
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose given to 34 children with anti-HBs titres lower or slightly higher than 100 IU l‐1
Trial: 23364004
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (10 μg vitamin D(3)/d and 1.2 g Ca/d, with 375 μg weekly)
Trial: 23364004
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent to 63 μg (2500 IU)/d and 10 μg (400 IU)/d)
Trial: 16160867
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.4 IU/kg)
Trial: 16734552
Drug: Insulin ultralente
RxNorm normalized name: INSULIN ULTRALENTE BEEF 100 U/ML IJ NOVO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin ultralente
Trial: 16734552
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.3 IU/kg)
Trial: 16734552
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (tailor-made dose)
Trial: 2423408
Drug: Amylase inhibitor
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylase inhibitor
Trial: 20545217
Drug: 0.0015% tafluprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0015% tafluprost ophthalmic solution
Trial: 16619567
Drug: PS76A2 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS76A2 (15 ng mistletoe lectin/0.5 ml)
Trial: 12746765
Drug: Fluconazole plus
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole plus placebo (800 mg per day)
Trial: 12746765
Drug: Fluconazole plus
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole plus amphotericin B (0.7 mg/kg per day for the first 5-6 days)
Trial: 7531023
Drug: Electrochemical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemical therapy (ECT) with systemic chemotherapy
Trial: 7531023
Drug: Electrochemical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemical therapy (ECT) alone
Trial: 7531023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (systemic chemotherapy alone)
Trial: 3279010
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg orally four times a day for 2 weeks)
Trial: 23649964
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg single oral dose in participants with mild hepatic impairment
Trial: 23649964
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg single oral dose in participants with moderate hepatic impairment
Trial: 23649964
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg single oral dose in participants with severe hepatic impairment
Trial: 23649964
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg single oral dose in healthy controls
Trial: 23649964
Drug: Brivaracetam metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam metabolism in hepatic impairment
Trial: 22191234
Drug: Phototherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapeutic treatment in addition to standard radio- and hormonal therapy (n=308)
Trial: 22191234
Drug: Standard radio-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radio- and hormonal therapy alone (n=251)
Trial: 19088057
Drug: Eccentric loading
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric loading plus shock-wave treatment
Trial: 17452150
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of pioglitazone
Trial: 15284252
Drug: Irinotecan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan treatment continued until disease progression (n = 25)
Trial: 15284252
Drug: Irinotecan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan treatment stopped after 8 cycles (n = 30)
Trial: 9754822
Drug: Linomide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide 2.5 mg
Trial: 2191485
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy (rt-PA)
Trial: 679080
Drug: Oral neomycin
RxNorm normalized name: neomycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neomycin and erythromycin base preoperatively
Trial: 31842026
Drug: Doxapram 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 1 mg/kg ideal body weight
Trial: 21710401
Drug: Second-Generation Antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-Generation Antipsychotics (SGAs)
Trial: 21710401
Drug: Drug company
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug company representatives as information source
Trial: 16001181
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day
Trial: 16001181
Drug: Control (alfacalcidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (alfacalcidol 1 mug/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day)
Trial: 15167985
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (10 min/day for 6 months)
Trial: 7534945
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Enoxaparin and Dextran
Trial: 3655512
Drug: Lateral subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral subcutaneous sphincterotomy
Trial: 26839889
Drug: MDI4 (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI4 (four injections daily, glargine based)
Trial: 26839889
Drug: MDI3 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI3 (three injections daily, aspart 30-based)
Trial: 24730050
Drug: Aerosolized albuterol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized albuterol (5mg q4h)
Trial: 22687231
Drug: Higher numbers
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher numbers of drugs prescribed during follow-up
Trial: 19248655
Drug: MA 60
RxNorm normalized name: Drizalma 60 MG Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 60 mg/kg/day/ IM and oral placebo for three weeks
Trial: 19248655
Drug: MA 30
RxNorm normalized name: Lasma 300 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 30 mg/kg/day/IM and oral omeprazole 40 mg/day for three weeks
Trial: 19248655
Drug: MA 30
RxNorm normalized name: Lasma 300 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 30 mg/kg/day/IM and oral placebo for three weeks
Trial: 10629357
Drug: eptastigmine 10
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: eptastigmine 10 mg t.i.d. and 12 mg t.i.d. for 25 weeks
Trial: 6827407
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (53 children)
Trial: 6827407
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (128 children)
Trial: 31123008
Drug: Amoxicillin 70-90
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 70-90 mg/kg/day for 3 or 7 days
Trial: 31123008
Drug: Amoxicillin 35-50
RxNorm normalized name: amoxicillin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 35-50 mg/kg/day for 3 or 7 days
Trial: 31123008
Drug: Amoxicillin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (both dosages)
Trial: 22002249
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment (simple, low-cost environmental modifications)
Trial: 22002249
Drug: Intense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense treatment (added elements to engage management)
Trial: 22002249
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment conditions (moderate vs. intense)
Trial: 17325603
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitor (NNRTI)
Trial: 17325603
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor + Nonnucleoside reverse transcriptase inhibitor (PI + NNRTI)
Trial: 11449531
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 800 micrograms/daily
Trial: 11449531
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 840 micrograms/daily
Trial: 9684692
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3) administered before meals
Trial: 9684692
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3) administered during meals
Trial: 7511495
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin (5% albumin solution)
Trial: 2894751
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) infusion (20 mU/kg/h)
Trial: 20052461
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg etoricoxib (n = 8)
Trial: 17117227
Drug: Intrapericardial triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapericardial triamcinolone hexacetonide 200 mg